EDINBURGH, UK. September 24th, 2024 – Edinburgh based Lentitek Ltd (Lentitek), a developer of a pioneering technology that can enable the delivery of advanced cell and gene therapies, announced today that it has appointed Dr Michael Roberts as a non-executive director.
The appointment of Dr Roberts significantly strengthens the Lentitek team both commercially and scientifically. Founded in 2019 by Dr Adam Inche, Lentitek had developed a technology which addresses key issues within the manufacturing of advanced cell and gene therapies. These advanced therapies provide curative treatments for previously intractable cancers and other genetic conditions but are difficult and expensive to manufacture and deliver. Since incorporation Lentitek has moved rapidly to develop and commercialise its unique technology attracting significant interest from major players in the field.
The appointment of Dr Roberts significantly strengthens the Lentitek team both commercially and scientifically. Founded in 2019 by Dr Adam Inche, Lentitek had developed a technology which addresses key issues within the manufacturing of advanced cell and gene therapies. These advanced therapies provide curative treatments for previously intractable cancers and other genetic conditions but are difficult and expensive to manufacture and deliver. Since incorporation Lentitek has moved rapidly to develop and commercialise its unique technology attracting significant interest from major players in the field.
Adam Inche, Chief Executive Officer of Lentitek commented: “It is with enormous pleasure that we welcome Dr Roberts to the Lentitek team. Michael brings a phenomenal depth of knowledge and experience both scientifically and commercially which will prove invaluable as we scale the business.
“Lentitek’s unique technology and application to advanced cell and gene therapy markets has close parallels to those which Dr Roberts commercialised so successfully at Synpromics. By leveraging his experience our team hopes to rapidly build on our strong initial successes in the market place.”
“Lentitek’s unique technology and application to advanced cell and gene therapy markets has close parallels to those which Dr Roberts commercialised so successfully at Synpromics. By leveraging his experience our team hopes to rapidly build on our strong initial successes in the market place.”
As a prominent scientist in the field of gene regulation, Dr Michael Roberts founded Synpromics in 2010, which pioneered the industrialisation of synthetic promoter design. After achieving significant commercial success in the cell and gene therapy space, Synpromics was acquired by Asklepios Biopharmaceuticals Inc (AskBio) in 2019.
On his appointment as Director at Lentitek, Dr Roberts commented: “I have been keenly interested in Lentitek and was delighted to be asked to join the team. Their technology provides an elegant solution to some of the most pressing concerns in lentivirus manufacturing.” Roberts currently serves as CEO for Chromatin Bioscience Ltd, a leading provider of synthetic promoter design services for the cell and gene therapy sector with a prestigious list clients.
On his appointment as Director at Lentitek, Dr Roberts commented: “I have been keenly interested in Lentitek and was delighted to be asked to join the team. Their technology provides an elegant solution to some of the most pressing concerns in lentivirus manufacturing.” Roberts currently serves as CEO for Chromatin Bioscience Ltd, a leading provider of synthetic promoter design services for the cell and gene therapy sector with a prestigious list clients.
Lentitek also recently secured a highly competitive Innovate UK grant for a £400,000 project to further develop its technology for cutting edge in-vivo CAR-T applications where the patients’ own immune cells are modified within the body rather than in a lab.
Lentitek Co-Founder Leif Anderson said: “Winning such a competitive grant is a tremendous endorsement of the technology and team Lentitek has built since incorporating. With Michael to guide us I believe the business is poised to make a real difference to the market and to patient outcomes."
More information can be found at the UKRI page.
ENDS
Lentitek Co-Founder Leif Anderson said: “Winning such a competitive grant is a tremendous endorsement of the technology and team Lentitek has built since incorporating. With Michael to guide us I believe the business is poised to make a real difference to the market and to patient outcomes."
More information can be found at the UKRI page.
ENDS
- Share This Article
Got News You'd Like To Share With The World? Our Press Release Distribution Starts At Just £95
